• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Another Sleeping Pill on the Market: Merck’s Belsomra

Another Sleeping Pill on the Market: Merck’s Belsomra

September 1, 2014
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Short Description:

Another Sleeping Pill on the Market: Merck’s Belsomra

Background:

The US Food and Drug Administration (FDA) last month approved Merck’s new insomnia drug, Belsomra, the first in a new class of hypnotics termed “orexin antagonists.” If you’ve never heard of orexin, put on your seat belts, because you’ll be getting a crash course from your local drug reps. Also known as hypocretins, orexins are chemicals discovered in 1998 that are secreted in the hypothalamus, and which normally function to keep us awake. It was only a matter of time before orexin blockers were developed, and Merck won the race. (TCPR will have a full take on Belsomra in our next issue.)

Generically known as suvorexant, Belsomra beats placebo in getting people to sleep, but it can cause next-day drowsiness and impaired driving. As a result, the FDA said that no more than one pill should be taken each night and the dose should not exceed 20 mg. The FDA is requiring that Merck continue to study next-day driving performance of patients taking the sedative. Belsomra is expected to be available in late 2014 or early 2015.

Impaired driving the morning after taking a sleeping pill is a phenomenon that has been recognized for more than a decade. The FDA first took action in January 2013 when it recommended cutting the dose of zolpidem (Ambien) by half, from 10 mg to 5 mg for immediate-release formulas, and from 12.5 mg to 6.25 mg for controlled-release formulas.

Results for Belsomra showed impaired driving in patients who took 20 mg. The FDA approved the drug in 5, 10, 15, and 20 mg doses. Merck had originally proposed that non-elderly adults start on 20 mg and increase to 40 mg if needed.

The recommended dose of Belsomra is 10 mg within 30 minutes of going to bed and patients then need to wait at least seven hours and be cautious about next-day driving.

The FDA also recommended that Belsomra be listed as a controlled substance because it can be addictive and has the potential to be abused (http://1.usa.gov/1qRWmaY). The Drug Enforcement Administration (DEA) is proposing that the drug be given a Schedule IV designation, the same as medications such as alprazolam (Xanax), clonazepam (Klonopin), and Ambien.

General Psychiatry
KEYWORDS news_of_note sleep_disorders
    www.thecarlatreport.com
    Issue Date: September 1, 2014
    SUBSCRIBE NOW
    Table Of Contents
    Step Right Up—Meaningful Use Incentives are Adding Up
    Op-Ed: Maintenance of Certification—Is it safe to opt out?
    Maintenance of Certification: What You Need to Know
    Using Transcranial Magnetic Stimulation (TMS) in Your Practice
    Mood Stabilizer Plus Antidepressant May Protect Against Mania
    CBT Moderately Effective in Improving Quality of Life for Anxiety Disorders
    Another Sleeping Pill on the Market: Merck’s Belsomra
    Should We Share Therapy Notes with Our Patients?
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.